Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.

Trial Details

NCT ID
NCT07486089
Phase
PHASE1 / PHASE2
Sponsor
Beijing Biotech
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Dual-target CAR-NK cells (EB-DT-CAR-NK)
  • Lymphodepleting chemotherapy
  • Supportive care
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Histologically confirmed breast carcinoma that is locally advanced, unresectable, or metastatic.
  • Disease subtype: HER2-positive breast cancer or triple-negative breast cancer (TNBC).
  • Progression after, intolerance to, or ineligibility for standard therapies appropriate for the disease subtype and line of therapy.
  • At least one measurable lesion per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →